AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|
4.8 C
New York
Saturday, November 14, 2026

Tag: results

newsFORsourcecompanycontentinformationreleases1IT

First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.

Shell second quarter 2025 update note

The following is an update to the second quarter 2025 outlook and gives an overview of our current expectations for the second quarter. Outlooks presented may vary from the actual second quarter 2025 results and are subject to finalisation of those results, which are scheduled to be published on July 31, 2025. Unless otherwise indicated, all outlook statements exclude identified items. 

ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)

Best Delta 8 Gummies of 2025: Area 52 Named #1 Edible by Oregon Observer

While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3 
While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3

Best THCA Vape of 2025 – Area 52 Named #1 Disposable by Oregon Observer

THCA Vapes Dominate Premium Cannabis Market as Area 52 Named Best THCA Vape of 2025 
THCA Vapes Dominate Premium Cannabis Market as Area 52 Named Best THCA Vape of 2025

CJ 4DPLEX Ignites Biggest Domestic Box Office Weekend in Company History

"Jurassic World Rebirth" Drove a Record-Setting Domestic Holiday Weekend for 4DX and SCREENX Formats BURBANK, Calif., July 6, 2025 /PRNewswire/ -- CJ 4DPLEX, a worldwide leading...

Hong Kong’s Digital Banking User Experience Survey 2025

Nearly a Quarter of Respondents Have a Poor Impression of Digital BanksOnly 30% of Users Prefer Digital Banks for Financial Management HONG KONG, July 7,...

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Human Clinical Trial of L-Ergothioneine (Dr.Ergo®) on Skin Health

SUSANNAH CONSTANTINE, 63, CHOOSES THE NEW ALMA HARMONY BIO-BOOST™ FOR MID-LIFE SKIN CONFIDENCE

*The Next Generation Collagen Laser Facial for glowing, smoother, firmer skin* The author, podcaster and TV personality Susannah Constantine, 63, opens up about confidence, ageing,...

JUICE PLUS LAUNCHES SUPERFOOD POWDER: A POWERHOUSE OF PLANT-BASED NUTRITION IN EVERY SIP

 Rated as having a 'Superior Taste'* with scientifically proven nutrients, and a rainbow of plant powders from 30 different fruits, vegetables, and berries in...

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe...

Webcast to be held Monday, July 7th at 8:00 a.m. ET 
Webcast to be held Monday, July 7th at 8:00 a.m. ET

ROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Petco Health and Wellness Company, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WOOF

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResults

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers